Publications by authors named "G Pompilio"
Article Synopsis
- The study aims to assess the safety and efficacy of using expanded CD34+ cells for treating patients with acute myocardial infarction (AMI) and reduced left ventricular function, crucial for improving patient outcomes.
- Patients with severe AMI (left ventricular ejection fraction <50%) are randomly assigned to receive either CD34+ cell treatment alongside standard care or standard care only, with a focus on monitoring major adverse cardiac events over six months.
- This trial is groundbreaking as it explores the automated expansion and administration of autologous CD34+ cells, addressing current technological limitations in cell therapy for heart recovery post-AMI.
Arrhythmogenic Cardiomyopathy (ACM) is a life-threatening, genetically determined disease primarily caused by mutations in desmosomal genes, such as PKP2. Currently, there is no etiological therapy for ACM due to its complex and not fully elucidated pathogenesis. Various cardiac cell types affected by the genetic mutation, such as cardiomyocytes (CM) and cardiac mesenchymal stromal cells (cMSC), individually contribute to the ACM phenotype, driving functional abnormalities and fibro-fatty substitution, respectively.
View Article and Find Full Text PDFBackground: To determine whether granulocyte colony-stimulating factor (G-CSF) improves clinical outcomes after large ST-elevation myocardial infarction (STEMI) when administered early in patients with left ventricular (LV) dysfunction after successful percutaneous coronary intervention (PCI).
Methods: STEM-AMI OUTCOME was designed as a prospective, multicentre, nationwide, randomised, open-label, phase III trial (ClinicalTrials.gov ID: NCT01969890) to demonstrate the efficacy and safety of early G-CSF administration in reducing 2-year cardiac mortality and morbidity in patients with STEMI with LV ejection fraction ≤45% after PCI.
Article Synopsis
- There is a significant gap in effective prevention and treatment methods for cardiovascular disease and microvascular complications caused by diabetes, despite extensive research on the underlying mechanisms.
- Recent studies suggest that epigenetic factors, like DNA methylation and histone modifications, may contribute to the development of these complications and can potentially be targeted for therapeutic purposes.
- This review highlights the links between diabetes and cardiovascular issues while discussing promising epigenetic drugs (or "epidrugs") that, although still in developmental stages, could offer new treatment options in the future.
Article Synopsis
- * Analyzed data from 7948 HF patients over a minimum of 2 years, employing topological data analysis (TDA) to find 19 patient clusters and trajectory analysis to outline disease evolution.
- * Findings included a 5-year survival rate across clusters ranging from 20% to 100%, with strong validation results from external and internal cohorts, confirming the reliability of the identified patient pathways.